Ex-Warp Speed vac­cine leader nabs NextGen funds for Mod­eX Ther­a­peu­tics’ Covid-19 an­ti­bod­ies

A for­mer leader of Op­er­a­tion Warp Speed’s vac­cines ef­fort, which led to a quick roll­out of Covid jabs, is get­ting fed­er­al fund­ing for his biotech’s work on the next gen­er­a­tion of Covid ther­a­peu­tics.

As part of the US gov­ern­ment’s $5 bil­lion Project NextGen, John Mas­co­la’s Mod­eX Ther­a­peu­tics will re­ceive an ini­tial $59 mil­lion to get a mul­ti­spe­cif­ic an­ti­body in­to and through a Phase I tri­al as a po­ten­tial tool for thwart­ing fu­ture SARS-CoV-2 vari­ants. Mas­co­la joined the OP­KO Health-owned Mod­eX in 2022 as chief sci­en­tif­ic of­fi­cer af­ter steer­ing Warp Speed’s vac­cine work and serv­ing as di­rec­tor of the NIH’s Vac­cine Re­search Cen­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER